Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib

Drug Des Devel Ther. 2023 Nov 15:17:3429-3437. doi: 10.2147/DDDT.S426898. eCollection 2023.

Abstract

Anti-angiogenesis therapy plays a vital role in the treatment of tumors, with anlotinib as its representative targeted drug. Anlotinib is a novel oral tyrosine kinase inhibitor (TKI) with inhibitory effects on tumor growth tumor angiogenesis. In Phase III clinical trials, anlotinib demonstrated better overall survival and progression-free survival than placebo in patients with advanced non-small cell lung cancer (NSCLC), and was approved for the first time as a third-line treatment for refractory advanced NSCLC. Going far beyond that, anlotinib has shown encouraging results in a variety of malignancies, including medullary thyroid carcinoma, renal cell carcinoma, gastric cancer and esophageal squamous cell carcinoma. Nevertheless, anlotinib has been subject to some controversy in terms of adverse events due to its widespread use. In this review, the mechanism of action, pharmacokinetic characteristics, adverse reactions in clinical use and management of anlotinib were summarized.

Keywords: adverse drug reaction; anlotinib; anti-angiogenesis; anti-cancer mechanism; non-small cell lung cancer.

Publication types

  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Clinical Trials, Phase III as Topic
  • Drug-Related Side Effects and Adverse Reactions* / drug therapy
  • Esophageal Neoplasms* / drug therapy
  • Esophageal Squamous Cell Carcinoma* / drug therapy
  • Humans
  • Kidney Neoplasms* / drug therapy
  • Lung Neoplasms* / drug therapy
  • Quinolines* / adverse effects

Substances

  • anlotinib
  • Quinolines

Grants and funding

There is no funding to report.